Swartz R D, Legault D J
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, 48109-0364, USA.
Am J Med. 1996 Mar;100(3):308-12. doi: 10.1016/S0002-9343(97)89489-2.
Intraperitoneal deferoxamine is a well established treatment for aluminum accumulation syndrome in patients with end-stage renal disease receiving peritoneal dialysis, but the use of intraperitoneal deferoxamine has not been described outside of the setting of chronic renal failure. We present here a case of secondary hemochromatosis, complicated by cirrhosis and cardiomyopathy, in which a chronic peritoneal dialysis catheter was used both to treat ascites and to deliver parenteral deferoxamine for iron overload. Daily urinary iron excretion was similar to that achieved when using standard routes of deferoxamine administration. Over a 2-year period, reversal of both the biochemical indicators and the clinical manifestations of iron overload was accomplished.
腹膜内去铁胺是治疗接受腹膜透析的终末期肾病患者铝蓄积综合征的一种成熟疗法，但除慢性肾衰竭情况外，腹膜内去铁胺的使用尚未见报道。我们在此报告一例继发性血色素沉着症，并发肝硬化和心肌病，其中使用慢性腹膜透析导管既用于治疗腹水，也用于输注胃肠外去铁胺以治疗铁过载。每日尿铁排泄量与使用标准去铁胺给药途径时所达到的排泄量相似。在两年时间里，实现了铁过载的生化指标和临床表现的逆转。
